Di Marzo V, Bifulco M, De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov. 2004;3(9):771–84.

Article  PubMed  Google Scholar 

Pacher P, Bátkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev. 2006;58(3):389–462.

Article  CAS  PubMed  Google Scholar 

Farrelly KN, Wardell JD, Marsden E, Scarfe ML, Najdzionek P, Turna J et al. The impact of recreational Cannabis legalization on Cannabis Use and Associated outcomes: a systematic review. Subst Abus Res Treat. 2023;17:1–22

Köck P, Lang E, Trulley VN, Dechent F, Mercer-Chalmers-Bender K, Frei P, et al. Cannabidiol Cigarettes as Adjunctive Treatment for psychotic disorders– a randomized, open-label pilot-study. Front Psychiatry. 2021;12(November):1–11.

Google Scholar 

Baltes-Flueckiger L, Steinauer R, Meyer M, Vogel M, Walter M. Effects of cannabis regulation in Switzerland: study protocol of a randomized controlled trial. Front Psychiatry. 2023;14(March):1–11.

Mosandl CF, Baltes-Flückiger L, Kronschnabel J, Meyer M, Guessoum A, Herrmann O, et al. Cannabis use and its association with psychopathological symptoms in a Swiss adult population: a cross-sectional analysis. Front Public Heal. 2024;12(May):1–11.

Google Scholar 

Cairns EA, Benson MJ, Bedoya-Pérez MA, Macphail SL, Mohan A, Cohen R, et al. Medicinal cannabis for psychiatry-related conditions: an overview of current Australian prescribing. Front Pharmacol. 2023;14(June):1–19.

Google Scholar 

Mahabir VK, Merchant JJ, Smith C, Garibaldi A. Medical cannabis use in the United States: a retrospective database study. J Cannabis Res. 2020;2(1):32.

Article  PubMed  PubMed Central  Google Scholar 

Solmi M, Radua J, Olivola M, Croce E, Soardo L, Salazar de Pablo G, et al. Age at onset of mental disorders worldwide: large-scale meta-analysis of 192 epidemiological studies. Mol Psychiatry. 2022;27(1):281–95.

Article  CAS  PubMed  Google Scholar 

Antolini G, Colizzi M. Where do neurodevelopmental disorders go? Casting the Eye away from Childhood towards Adulthood. Healthc. 2023;11(7):1–22.

Article  Google Scholar 

Chadwick O, Kusel Y, Cuddy M. Factors associated with the risk of behaviour problems in adolescents with severe intellectual disabilities. J Intellect Disabil Res. 2008;52(10):864–76.

Article  CAS  PubMed  Google Scholar 

Semovski V, King C, Lapshina N, Stewart SL. A cross-sectional examination of service complexity in youths with co-occurring autism spectrum disorder and psychiatric or medical diagnoses across service sectors. Front Psychol. 2023;13(February):1–16.

Google Scholar 

Sheehan R, Hassiotis A, Walters K, Osborn D, Strydom A, Horsfall L. Mental illness, challenging behaviour, and psychotropic drug prescribing in people with intellectual disability: UK Population based cohort study. BMJ. 2015;351.:1–9

Ninan A, Stewart SL, Theall LA, Katuwapitiya S, Kam C. Adverse effects of psychotropic medications in children: predictive factors. J Can Acad Child Adolesc Psychiatry. 2014;23(3):218–25.

PubMed  PubMed Central  Google Scholar 

Rapoport JL. Pediatric psychopharmacology: too much or too little? World Psychiatry. 2013;12(2):118–23.

Article  PubMed  PubMed Central  Google Scholar 

Rao P, Morandini H. Newer modalities in psychopharmacology in children and adolescents: a selective narrative review of the literature. J Indian Assoc Child Adolesc Ment Heal. 2023;19(1):88–94.

Google Scholar 

Efron D, Taylor K. Medicinal Cannabis for paediatric developmental, behavioural and mental health disorders. Int J Environ Res Public Health. 2023;20(8).:1–15

Rice LJ, Cannon L, Dadlani N, Cheung MMY, Einfeld SL, Efron D, et al. Efficacy of cannabinoids in neurodevelopmental and neuropsychiatric disorders among children and adolescents: a systematic review. Eur Child Adolesc Psychiatry. 2024;33(2):505–26.

Article  PubMed  Google Scholar 

Black N, Stockings E, Campbell G, Tran LT, Zagic D, Hall WD, et al. Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis. Lancet Psychiatry. 2019;6(12):995–1010.

Article  PubMed  PubMed Central  Google Scholar 

Hill KP, Gold MS, Nemeroff CB, McDonald W, Grzenda A, Widge AS, et al. Risks and benefits of Cannabis and cannabinoids in Psychiatry. Am J Psychiatry. 2022;179(2):98–109.

Article  PubMed  Google Scholar 

Sarris J, Sinclair J, Karamacoska D, Davidson M, Firth J. Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review. BMC Psychiatry. 2020;20(1):1–14.

Article  Google Scholar 

Dammann I, Rohleder C, Leweke FM. Cannabidiol and its potential evidence-based Psychiatric benefits - a critical review. Pharmacopsychiatry. 2024;57(3):115–32.

Article  PubMed  Google Scholar 

Solmi M, De Toffol M, Kim JY, Choi MJ, Stubbs B, Thompson T et al. Balancing risks and benefits of cannabis use: Umbrella review of meta-analyses of randomised controlled trials and observational studies. BMJ. 2023;61.:1–19

Silvestro S, Mammana S, Cavalli E, Bramanti P, Mazzon E. Use of Cannabidiol in the treatment of Epilepsy: efficacy and security in clinical trials. Molecules. 2019;24(8).:1–25

Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV, et al. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA - J Am Med Assoc. 2015;313(24):2456–73.

Article  CAS  Google Scholar 

Bruni N, Della Pepa C, Oliaro-Bosso S, Pessione E, Gastaldi D, Dosio F. Cannabinoid Delivery systems for pain and inflammation treatment. Molecules. 2018;23(10).:1–25

Leung J, Chan G, Stjepanović D, Chung JYC, Hall W, Hammond D. Prevalence and self-reported reasons of cannabis use for medical purposes in USA and Canada. Psychopharmacology. 2022;239(5):1509–19.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wallis D, Coatsworth JD, Mennis J, Riggs NR, Zaharakis N, Russell MA, et al. Predicting Self-Medication with Cannabis in Young adults with hazardous Cannabis Use. Int J Environ Res Public Health. 2022;19(3):1–15.

Article  Google Scholar 

Wade NE, Nguyen-Louie TT, Wallace AL, Sullivan RM, Tapert SF. Commercial cannabidiol for community-based young adolescents: Predicting Medicinal Use. Cannabis Cannabinoid Res. 2024;X(X):1–9.

Google Scholar 

Smith CJ, Vergara D, Keegan B, Jikomes N. The phytochemical diversity of commercial Cannabis in the United States. PLoS ONE. 2022;17(5):e0267498.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lafaye G, Karila L, Blecha L, Benyamina A. Cannabis, cannabinoids, and health. Dialogues Clin Neurosci. 2017;19(3):309–16.

Article  PubMed  PubMed Central  Google Scholar 

Mazzetti C, Ferri E, Pozzi M, Labra M. Quantification of the content of cannabinol in commercially available e-liquids and studies on their thermal and photo-stability. Sci Rep. 2020;10(1):6–11.

Article  Google Scholar 

Quiñones R, Moreno S, Smythers AL, Sullins C, Pijor H, Brown G, et al. Quantification of Cannabis in Infused Consumer products and their residues on skin. ACS Pharmacol Transl Sci. 2022;5(8):642–51.

Article  PubMed  PubMed Central  Google Scholar 

NICE Clinical Guideline Team. Cannabis-based products for medicinal use| Guidance| NICE. Nice. 2019;1–12.

Aizpurua-Olaizola O, Soydaner U, Öztürk E, Schibano D, Simsir Y, Navarro P, et al. Evolution of the cannabinoid and terpene content during the growth of Cannabis sativa plants from different chemotypes. J Nat Prod. 2016;79(2):324–31.

Article  CAS  PubMed  Google Scholar 

Schurman LD, Lu D, Kendall DA, Howlett AC, Lichtman AH. Molecular mechanism and cannabinoid pharmacology. Handb Exp Pharmacol. 2020;258:323–53.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Behl T, Makkar R, Sehgal A, Singh S, Makeen HA, Albratty M et al. Exploration of Multiverse activities of endocannabinoids in Biological systems. Int J Mol Sci. 2022;23(10).:1–23

Kitchigina VF. Cannabinoids, the Endocannabinoid System, and cognitive functions: enemies or friends? Neurosci Behav Physiol. 2021;51(7):893–914.

Article  CAS  Google Scholar 

Garani R, Watts JJ, Mizrahi R. Endocannabinoid system in psychotic and mood disorders, a review of human studies. Prog Neuro-Psychopharmacology Biol Psychiatry. 2021;106(August 2020):110096.

Stampanoni Bassi M, Gilio L, Maffei P, Dolcetti E, Bruno A, Buttari F, et al. Exploiting the multifaceted effects of cannabinoids on mood to boost their therapeutic use against anxiety and depression. Front Mol Neurosci. 2018;11(November):1–11.

Google Scholar 

D’Angelo M, Steardo L. Cannabinoids and sleep: exploring Biological mechanisms and therapeutic potentials. Int J Mol Sci. 2024;25(7).:1–12

Lu HC, Mackie K. Review of the Endocannabinoid System. Biol Psychiatry Cogn Neurosci Neuroimaging. 2021;6(6):607–15.

PubMed  Google Scholar 

Bie B, Wu J, Foss JF, Naguib M. An overview of the cannabinoid type 2 receptor system and its therapeutic potential. Curr Opin Anaesthesiol. 2018;31(4):407–14.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Minichino A, Senior M, Brondino N, Zhang SH, Godwlewska BR, Burnet PWJ, et al. Measuring disturbance of the Endocannabinoid System in psychosis: a systematic review and Meta-analysis. JAMA Psychiatry. 2019;76(9):914–23.

Article  PubMed  PubMed Central  Google Scholar 

Su T, Yan Y, Li Q, Ye J, Pei L. Endocannabinoid System unlocks the puzzle of Autism Treatment via Microglia. Front Psychiatry. 2021;12:734837.

Article  PubMed  PubMed Central